Eli Lilly Canada Inc. v. Novopharm Limited, 2010 FCA 197 (Olanzapine*)
Justice Nadon; Justice Sharlow; Justice Layden-Stevenson - 2010-07-21
Read full decision. Automatically generated summary:
The plaintiffs (Lilly) commenced an action for patent infringement against the defendant (Novopharm) with respect to Canadian Letters Patent No. 2,041,113 (the '113 Patent), a selection patent for the compound olanzapine (sold under the brand name Zyprexa), owned by Lilly. Olanzapine is used to treat schizophrenia.
Decision relates to:
- A-454-09 - ELI LILLY CANADA INC. ET AL v. NOVOPHARM LIMITED which is an appeal from 2009 FC 1018 in T-1048-07